VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 30, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News; Frankfurt/FSE:MIV), a developer of next-generation biocompatible stent coatings and drug delivery technologies, announced the availability of a new research report targeting the Company's six-month share price at $2.50, an approximate doubling of the recent share value, with a speculative Buy/4 Rating. The report was issued by SISM Research and Investment Services.

ADVERTISEMENT

In the report, author Ernest C. Schlotter, Senior Analyst with SISM, notes that MIVT is significantly undervalued with a current market cap of only $75 million, far less than comparable biotech companies. He projects an MIVT market capitalization potential of $250 million, still a 50 percent markdown compared to those of similar companies.

"MIVT gained investors' confidence based on very encouraging results from its latest animal trials which pave the way for human clinical trials scheduled to commence in late 2005 or in early 2006," Mr. Schlotter wrote. "MIV Therapeutics also won the prestigious Frost & Sullivan 2005 Technology Innovation Award for Advanced Medical Coatings. Frost & Sullivan singled out MIVT as a leader in the large and important medical coatings sector."

In the three months since SISM's last published report, MIVT stock has already soared to roughly three times its previous price, according to Mr. Schlotter, yet still remains markedly below a fair value. "Since our last update on June 2005, the stock has tripled in price but there is still considerable value to be unlocked," he writes in the report.

Among the Company's potentially significant milestones is its previously announced planned acquisition of advanced international stent manufacturer Sahajanand Medical Technologies (SMT), according to Mr. Schlotter.

"The planned acquisition of SMT would provide a powerful synergy that will make MIVT a major industry player," the report noted. "SMT's state-of-the-art production technology and worldwide distribution, combined with MIVT's proprietary coating technology, will provide a powerful synergy that will make MIVT a major industry player...in the rapidly growing market for both cardiac and other types of implantable medical devices."

Mr. Schlotter notes that the Company's growing recognition as a leading coatings and drug delivery innovator bodes well for increased visibility and awareness within the investor community. MIVT has developed a line of advanced biomedical coatings based on a highly biocompatible material called Hydroxyapatite (HAp), which has been shown to be suitable for a broad array of applications as a coating for coronary stents and next-generation drug-elution/drug-delivery systems. In addition, the report notes, MIVT's proprietary HAp coating technologies are increasingly being recognized for their ability to provide exceptional degrees of biocompatibility compared to traditional bare metal stents and less advanced polymer coating alternatives now available in the marketplace. MIVT's suite of HAp-based coatings enables the surface of metallic stents to virtually mimic the natural state of structurally-sound 100% biocompatible and bio-active tissue. The company's portfolio of innovative technologies also includes breakthrough composite drug-eluting systems for a broad range of potential medical applications.

Among the key scientific and financial assets illuminated in the current SISM report are the following:

• MIVT's HAp-based stent coatings have demonstrated exceptional performance and biocompatibility in key areas of its ongoing in vivo pig implantation trials. "Stents coated with HAp showed no elevated inflammatory response, especially when compared with bare metal stents, suggesting excellent biocompatibility, with low neointimal thickness."
• MIVT closed a $4.14 million fundraiser in August; the money will be sufficient to support the ongoing needs for the Company's operations and research program and preparations for human trials.

"The present status of quickly maturing MIVT technology offers an exceptionally favorable risk/reward for risk-tolerant, capital gains oriented investor who believes in the long-term growth and profit potential of the Company," according to the report.

The full SISM Research report can be found at http://www.BiomedDiscoveries.com.

About SISM Research

SISM Research, based in Zurich, Switzerland, is a private investment research firm offering high-quality, independent, fundamental research on public companies since 1995. SISM writes, publishes and distributes research coverage, in both English and German, on micro- to small-cap public companies trading on the OTC Bulletin Board, NASDAQ and AMEX. This coverage is geared toward institutional and individual investors in both North America and in German-speaking Europe, a market that represents more than 100 million people. SISM Research is a content provider to Thomson Financials OneAnalytics/FirstCall, to Multex, and InvesTrend. Both SISM Research and InvesTrend Research subscribe to the "Standards for Independent Research Providers." MIV Therapeutics will pay SISM Research $1,750 per month over a two-year period solely to ensure independent coverage.

About MIV Therapeutics, Inc.

MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company's drug eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit: http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is also traded on the Frankfurt Stock Exchange under the ticker symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

---

Contact:

     MIV Therapeutics, Inc.
     Investor Relations, 604-301-9545
     Toll-free: 800-221-5108
     Fax: 604-301-9546
     E-mail: investor@mivtherapeutics.com
     Web: www.mivtherapeutics.com
     Or for Product Inquiries and Business Opportunities:
     Arc Rajtar, 604-301-9545 Ext. 22
     arajtar@mivi.ca
     or
     Trilogy Capital Partners
     Paul Karon, Toll-free: 800-342-1467
     paul@trilogy-capital.com